Verastem, Inc. reported $88M of revenue over the trailing twelve months, +3996% on the year before. 9 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $88M (to Q2 2026). Net income: −$203M, trailing twelve months to Q2 2026. Operating margin: −230%, trailing twelve months to Q2 2026. EPS: −$2.45, trailing twelve months to Q2 2026.

VSTMVerastem, Inc.

Healthcare

$3.45-24% 1Y

$3.45

$3.4552 weeks$10.64

VSTM as reported

Verastem, Inc. reported $88M of revenue over the trailing twelve months, +3996% on the year before. 9 reported series are charted on this page, each one as filed.

$88M

Revenue, trailing twelve months · to Q2 2026 · +3996% against the twelve months before

Net income: −$203M
Net income · +22% year on year · trailing twelve months to Q2 2026
Operating margin: −230%
Operating margin · trailing twelve months to Q2 2026
EPS: −$2.45
EPS · −34% year on year · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for VSTM, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$88M	+3996%	Q2 2026
Net income	−$203M	+22%	Q2 2026
EPS	−$2.45	−34%	Q2 2026
Operating margin	−230%	n/a	Q2 2026
Net margin	−337%	n/a	Q2 2026
ROE	136%	n/a	Q2 2026
ROA	−101%	n/a	Q2 2026
ROIC	92%	n/a	Q3 2025
Free cash flow	−$105M	n/a	Q4 2024 · 6 quarters behind

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.